Tokyo Tape
Sign in
← Carna Biosciences

Quarterly report · Q1

4572.TEDINET S100TC6I
Period2024-01-01 → 2024-03-31
Filed2024-05-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥181m2024-01-01 → 2024-03-31Cons.Net sales
Revenue¥1.6bn2023-01-01 → 2023-12-31Cons.Net sales (5-year summary)
Revenue¥227m2023-01-01 → 2023-03-31Cons.Net sales
Operating income−¥416m2024-01-01 → 2024-03-31Cons.Operating income
Operating income−¥506m2023-01-01 → 2023-03-31Cons.Operating income
Ordinary income−¥394m2024-01-01 → 2024-03-31Cons.Ordinary income
Ordinary income−¥1.1bn2023-01-01 → 2023-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥513m2023-01-01 → 2023-03-31Cons.Ordinary income
Profit before tax−¥397m2024-01-01 → 2024-03-31Cons.Income before income taxes
Profit before tax−¥514m2023-01-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)−¥399m2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.2bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥519m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income−¥399m2024-01-01 → 2024-03-31Cons.Profit loss
Net income−¥519m2023-01-01 → 2023-03-31Cons.Profit loss
Total assets¥3.9bnat 2024-03-31Cons.Assets
Total assets¥4.3bnat 2023-12-31Cons.Assets
Total assets¥4.9bnat 2023-03-31Cons.Total assets (5-year summary)
Total liabilities¥376mat 2024-03-31Cons.Liabilities
Total liabilities¥472mat 2023-12-31Cons.Liabilities
Net assets / equity¥3.5bnat 2024-03-31Cons.Net assets
Net assets / equity¥3.9bnat 2023-12-31Cons.Net assets
Net assets / equity¥4.4bnat 2023-03-31Cons.Net assets (5-year summary)
Cash and deposits¥3.2bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥2.9bnat 2023-12-31Cons.Cash and deposits
EPS (basic)¥-23.272024-01-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-68.622023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-32.782023-01-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio90.3%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.1%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio88.8%at 2023-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 8
SegmentItemPeriodValue
jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥418m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥181m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥181m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2024-01-01 → 2024-03-31¥1m
jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segmentsegment profit2023-01-01 → 2023-03-31−¥570m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥227m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥227m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2023-01-01 → 2023-03-31¥64m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 296
ItemContextValueUnit
Capital stockPrior1YearInstant2076474000JPY
Capital stockCurrentQuarterInstant2076474000JPY
Capital surplusPrior1YearInstant5827683000JPY
Capital surplusCurrentQuarterInstant5827683000JPY
Retained earningsPrior1YearInstant-4075386000JPY
Retained earningsCurrentQuarterInstant-4474276000JPY
Treasury stockPrior1YearInstant-222000JPY
Treasury stockCurrentQuarterInstant-222000JPY
Shareholders equityPrior1YearInstant3828549000JPY
Shareholders equityCurrentQuarterInstant3429658000JPY
Valuation difference on available for sale securitiesPrior1YearInstant-2722000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant-2952000JPY
Deferred gains or losses on hedgesPrior1YearInstant－JPY
Deferred gains or losses on hedgesCurrentQuarterInstant19240000JPY
Foreign currency translation adjustmentPrior1YearInstant51709000JPY
Foreign currency translation adjustmentCurrentQuarterInstant72025000JPY
Valuation and translation adjustmentsPrior1YearInstant48986000JPY
Valuation and translation adjustmentsCurrentQuarterInstant88313000JPY
Net assetsPrior1YearInstant3877535000JPY
Net assetsCurrentQuarterInstant3517971000JPY
Liabilities and net assetsPrior1YearInstant4349891000JPY
Liabilities and net assetsCurrentQuarterInstant3894220000JPY
Net salesPrior1YTDDuration226967000JPY
Net salesCurrentYTDDuration180870000JPY
Cost of salesPrior1YTDDuration48635000JPY
Cost of salesCurrentYTDDuration46670000JPY
Gross profitPrior1YTDDuration178332000JPY
Gross profitCurrentYTDDuration134199000JPY
Selling general and administrative expensesPrior1YTDDuration684125000JPY
Selling general and administrative expensesCurrentYTDDuration550439000JPY
Operating incomePrior1YTDDuration-505792000JPY
Operating incomeCurrentYTDDuration-416240000JPY
Interest income noiPrior1YTDDuration64000JPY
Interest income noiCurrentYTDDuration2517000JPY
Dividends income noiPrior1YTDDuration105000JPY
Dividends income noiCurrentYTDDuration109000JPY
Foreign exchange gains noiPrior1YTDDuration－JPY
Foreign exchange gains noiCurrentYTDDuration20122000JPY
Other noiPrior1YTDDuration23000JPY
Other noiCurrentYTDDuration22000JPY
Non operating incomePrior1YTDDuration193000JPY
Non operating incomeCurrentYTDDuration22771000JPY
Interest expenses noePrior1YTDDuration896000JPY
Interest expenses noeCurrentYTDDuration926000JPY
Guarantee commission noePrior1YTDDuration239000JPY
Guarantee commission noeCurrentYTDDuration99000JPY
Stock issuance cost noePrior1YTDDuration4618000JPY
Stock issuance cost noeCurrentYTDDuration－JPY
Foreign exchange losses noePrior1YTDDuration2015000JPY
Foreign exchange losses noeCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass